Abstract
G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Keywords: Protein-Coupling, transmembrane, SR141716A
Current Neuropharmacology
Title: Cannabinoid Receptor G Protein-Coupling and Inverse Agonism
Volume: 2 Issue: 1
Author(s): Deborah L. Lewis
Affiliation:
Keywords: Protein-Coupling, transmembrane, SR141716A
Abstract: G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Export Options
About this article
Cite this article as:
Lewis L. Deborah, Cannabinoid Receptor G Protein-Coupling and Inverse Agonism, Current Neuropharmacology 2004; 2 (1) . https://dx.doi.org/10.2174/1570159043476891
DOI https://dx.doi.org/10.2174/1570159043476891 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Properties of CA3 Dendritic Excrescences in Alzheimers Disease
Current Alzheimer Research Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies
Current Vascular Pharmacology Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Current Neuropharmacology Changes in Immune and Endocrine Systems in Scrapie-Infected Animals
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease
Current Alzheimer Research Cerebral Collateral Circulation in Carotid Artery Disease
Current Cardiology Reviews In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry Green Tea (Camellia sinensis) Protects Against Arsenic Neurotoxicity via Antioxidative Mechanism and Activation of Superoxide Dismutase Activity
Central Nervous System Agents in Medicinal Chemistry Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Correlation between Potassium Channel Expression and Sensitivity to Drug-induced Cell Death in Tumor Cell Lines
Current Pharmaceutical Design β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Current Pharmaceutical Design New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine The α2δ Subunit and Absence Epilepsy: Beyond Calcium Channels?
Current Neuropharmacology Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Current Molecular Medicine Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Microenvironmental Determinants of Adult Neural Stem Cell Proliferation and Lineage Commitment in the Healthy and Injured Central Nervous System
Current Stem Cell Research & Therapy